Informazione
Precautions The use of harpagophytum is not recommended before the age of 18, or in pregnant or lactating People with heart problems, hyper or hypotension. Diabetics: harpagophytum lowers blood glucose levels. Monitor blood glucose carefully. Contraindications Gastric and duodenal ulcers In case of stones (stones) gall, the harpagophytum decision can only be considered after consulting a doctor (increase bile production by the Devil's Claw). Diabetes unbalanced side effects generally well tolerated at recommended doses can sometimes note benign disorders such as diarrhea, abdominal pain or gastrointestinal disorders. Some cases of allergic skin manifestations and headache have been reported. Oral antidiabetic Interactions: Increased hypoglycemic effect. When used in combination, carefully monitor your blood sugar. Inhibitors of proton pump (PPI) decreased activity of PPI Harpagophytum inhibit the action of PPIs increased production of gastric acid. When used in combination, monitoring of clinical signs of inefficiency (gastric pain unrelieved). Warfarin: increased activity of the anticoagulant so the risk of bleeding is increased. When used in combination, careful monitoring of clinical signs of bleeding. The combination should be avoided. Antiplatelet agents: increased antiplatelet effect In case of association, rigorous monitoring of clinical signs of hemorrhage. The combination should be avoided. Increased hypoglycemic effect. When used in combination, carefully monitor your blood sugar. Inhibitors of proton pump (PPI) decreased activity of PPI Harpagophytum inhibit the action of PPIs increased production of gastric acid. When used in combination, monitoring of clinical signs of inefficiency (gastric pain unrelieved). Warfarin: increased activity of the anticoagulant so the risk of bleeding is increased. When used in combination, careful monitoring of clinical signs of bleeding. The combination should be avoided. Antiplatelet agents: increased antiplatelet effect In case of association, rigorous monitoring of clinical signs of hemorrhage. The combination should be avoided. Increased hypoglycemic effect. When used in combination, carefully monitor your blood sugar. Inhibitors of proton pump (PPI) decreased activity of PPI Harpagophytum inhibit the action of PPIs increased production of gastric acid. When used in combination, monitoring of clinical signs of inefficiency (gastric pain unrelieved). Warfarin: increased activity of the anticoagulant so the risk of bleeding is increased. When used in combination, careful monitoring of clinical signs of bleeding. The combination should be avoided. Antiplatelet agents: increased antiplatelet effect In case of association, rigorous monitoring of clinical signs of hemorrhage. The combination should be avoided. Inhibitors of proton pump (PPI) decreased activity of PPI Harpagophytum inhibit the action of PPIs increased production of gastric acid. When used in combination, monitoring of clinical signs of inefficiency (gastric pain unrelieved). Warfarin: increased activity of the anticoagulant so the risk of bleeding is increased. When used in combination, careful monitoring of clinical signs of bleeding. The combination should be avoided. Antiplatelet agents: increased antiplatelet effect In case of association, rigorous monitoring of clinical signs of hemorrhage. The combination should be avoided. Inhibitors of proton pump (PPI) decreased activity of PPI Harpagophytum inhibit the action of PPIs increased production of gastric acid. When used in combination, monitoring of clinical signs of inefficiency (gastric pain unrelieved). Warfarin: increased activity of the anticoagulant so the risk of bleeding is increased. When used in combination, careful monitoring of clinical signs of bleeding. The combination should be avoided. Antiplatelet agents: increased antiplatelet effect In case of association, rigorous monitoring of clinical signs of hemorrhage. The combination should be avoided. monitoring of clinical signs of inefficiency (gastric pain unrelieved). Warfarin: increased activity of the anticoagulant so the risk of bleeding is increased. When used in combination, careful monitoring of clinical signs of bleeding. The combination should be avoided. Antiplatelet agents: increased antiplatelet effect In case of association, rigorous monitoring of clinical signs of hemorrhage. The combination should be avoided. monitoring of clinical signs of inefficiency (gastric pain unrelieved). Warfarin: increased activity of the anticoagulant so the risk of bleeding is increased. When used in combination, careful monitoring of clinical signs of bleeding. The combination should be avoided. Antiplatelet agents: increased antiplatelet effect In case of association, rigorous monitoring of clinical signs of hemorrhage. The combination should be avoided. rigorous monitoring of clinical signs of hemorrhage. The combination should be avoided. rigorous monitoring of clinical signs of hemorrhage. The combination should be avoided.
Rischi
See below
Tutte queste raccomandazioni sono fornite solo a scopo informativo, non possono sostituire il parere del proprio medico
